| Tag | Content |
|---|---|
| UniProt Accession | GDIR1_HUMAN; P52565; |
| Entrez ID | 396 |
| GenBank Protein ID | NM_001185077.2; NM_001185078.2; NM_001301240.1; NM_001301241.1; NM_001301242.1; NM_001301243.1; NM_004309.5; |
| GenBank Nucleotide ID | NP_001172006.1; NP_001172007.1; NP_001288169.1; NP_001288170.1; NP_001288171.1; NP_001288172.1; NP_004300.1; |
| Protein Name | Rho GDP-dissociation inhibitor 1 (Rho GDI 1) (Rho-GDI alpha) |
| Gene Name | ARHGDIA; GDIA1 |
| Organism | Homo sapiens |
| NCBI Taxa ID | 9606 |
| Functional Description | Controls Rho proteins homeostasis. Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them. Retains Rho proteins such as CDC42, RAC1 and RHOA in an inactive cytosolic pool, regulating their stability and protecting them from degradation. Actively involved in the recycling and distribution of activated Rho GTPases in the cell, mediates extraction from membranes of both inactive and activated molecules due its exceptionally high affinity for prenylated forms. Through the modulation of Rho proteins, may play a role in cell motility regulation. In glioma cells, inhibits cell migration and invasion by mediating the signals of SEMA5A and PLXNB3 that lead to inactivation of RAC1. |
| Sequence (Fasta) | MAEQEPTAEQ LAQIAAENEE DEHSVNYKPP AQKSIQEIQE LDKDDESLRK YKEALLGRVA 60 VSADPNVPNV VVTGLTLVCS SAPGPLELDL TGDLESFKKQ SFVLKEGVEY RIKISFRVNR 120 EIVSGMKYIQ HTYRKGVKID KTDYMVGSYG PRAEEYEFLT PVEEAPKGML ARGSYSIKSR 180 FTDDDKTDHL SWEWNLTIKK DWKD 205 |
|
||||||||||||||||||||
| Database | Annotation |
|---|---|
| CTD (Curated) (count: 5) | MESH:D001943
; Breast Neoplasms MESH:D015658 ; HIV Infections MESH:D007627 ; Keloid MESH:D009362 ; Neoplasm Metastasis OMIM:615244 ; NEPHROTIC SYNDROME, TYPE 8 |
| DisGeNet (Curated) (count: 25) (view all) | C0013604; Edema
C0018784; Sensorineural Hearing Loss (disorder) C0019693; HIV Infections C0022548; Keloid C0025362; Mental Retardation C0027627; Neoplasm Metastasis |
| PTM | Modification Sites |
|---|---|
| Phosphorylation (count: 14) (view all) | 101 LESFKKQSFVLKEGV dbPAF
132 GMKYIQHTYRKGVKI dbPAF 133 MKYIQHTYRKGVKID dbPAF 144 VKIDKTDYMVGSYGP dbPAF 156 YGPRAEEYEFLTPVE dbPAF 174 KGMLARGSYSIKSRF dbPAF |
| Acetylation (count: 9) (view all) | 105 KKQSFVLKEGVEYRI PLMD
127 REIVSGMKYIQHTYR PLMD 138 HTYRKGVKIDKTDYM PLMD 141 RKGVKIDKTDYMVGS PLMD 167 TPVEEAPKGMLARGS PLMD 178 ARGSYSIKSRFTDDD PLMD |
| Ubiquitination (count: 10) (view all) | 127 REIVSGMKYIQHTYR PLMD
138 HTYRKGVKIDKTDYM PLMD 141 RKGVKIDKTDYMVGS PLMD 167 TPVEEAPKGMLARGS PLMD 178 ARGSYSIKSRFTDDD PLMD 186 SRFTDDDKTDHLSWE PLMD |
| Sumoylation (count: 2) | 138 HTYRKGVKIDKTDYM PLMD
141 RKGVKIDKTDYMVGS PLMD |
| Glycation (count: 2) | 138 HTYRKGVKIDKTDYM PLMD
167 TPVEEAPKGMLARGS PLMD |
| Malonylation (count: 6) | 127 REIVSGMKYIQHTYR PLMD
138 HTYRKGVKIDKTDYM PLMD 141 RKGVKIDKTDYMVGS PLMD 178 ARGSYSIKSRFTDDD PLMD 43 QEIQELDKDDESLRK PLMD 99 GDLESFKKQSFVLKE PLMD |
| Methylation (count: 2) | 50 KDDESLRKYKEALLG PLMD
52 DESLRKYKEALLGRV PLMD |
| Succinylation (count: 3) | 105 KKQSFVLKEGVEYRI PLMD
178 ARGSYSIKSRFTDDD PLMD 43 QEIQELDKDDESLRK PLMD |
| Network | Interaction | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | Source | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||